SVRA - サバラ （Savara Inc.）

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2023 at 10:30 am ET/7:30 am PT. A live webcast of the fireside chat will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. About Savara Savara is a clinical s

The company released first-quarter earnings and said it had completed a phase 3 trial enrollment for its lead therapy.

Savara (SVRA) shares gained Tuesday after Jefferies upgraded it to Buy citing over 100% upside from a positive Phase 3 readout for its lead asset. Read more here.

https://www.investing.com/news/pro/mast-therapeutics-receives-investment-bank-analyst-rating-update-3047692

Savara press release (SVRA): Q4 GAAP EPS of -$0.07.As of December 31, 2022, the Company had cash, cash equivalents and short-term investments of $125.9 million.

Savara’s exit comes a year after Zomato co-founder Gaurav Gupta quit expressing his desire to pursue his own venture

Savara (SVRA) said on Aug. 25 that the U.K.''s Medicines and Healthcare Products Regulatory Agency ((MHRA)) granted promising innovative medicine ((PIM)) designation to molgramostim…

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) granted Promising Innovative Medicine (PIM) designation to molgramostim for the treatment of aPAP, a rare lung disease with no approved pharmaceutical treatments. PIM designation is an early indication that molgramostim is a promising candidate for the EAMS, a program

Savara (NASDAQ: SVRA ) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Savara reported in-line EPS of $-0.06 versus … Full story available on Benzinga.com

Savara press release (SVRA): Q2 GAAP EPS of -$0.06 in-line.“Despite ongoing factors such as geographical COVID surges, geopolitical issues and supply chain constraints, IMPALA-2,…

Savara entered into a $26.5M term loan agreement with Silicon Valley Bank to replace its existing credit facility with the bank.

Savara press release (SVRA): Q4 GAAP EPS of -$0.07 in-line.As of December 31, 2021, the Company had cash, cash equivalents and short-term investments of $161.2 million.

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, reported financial results for the fourth quarter and full year ending December 31, 2021 and provided a business update. “The company underwent a significant amount of positive change in 2021. We streamlined the pipeline to focus solely on the molgramostim development program, strengthened our management team with key hires in clinical, regulatory, and CMC and improved our financial position with a $130M

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at Oppenheimer’s 32nd Annual Healthcare Conference on March 16, 2022 at 3:20 pm ET. A live webcast of the presentation will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical

Savara Inc (NASDAQ:SVRA) Director David A. Ramsay acquired 25,000 shares of the companys stock in a transaction dated Friday, December 17th. The stock was acquired at an average price of $1.13 per share, for a total transaction of $28,250.00. The purchase was disclosed in a legal filing with the SEC, which is available at the []